Literature DB >> 23657302

Progression of liver fibrosis in monoinfected patients by hepatitis C virus and coinfected by HCV and human immunodeficiency virus.

Cristiane Valle Tovo1, Smile Calisto da Costa Becker, Paulo Roberto Lerias de Almeida, Bruno Galperim, Silvia Chaves.   

Abstract

CONTEXT: The progression of liver fibrosis in patients coinfected by hepatitis C virus and human immunodeficiency virus (HCV/HIV) has been increasingly studied in the past decade. Studies made before the highly active antiretroviral therapy suggest that HIV can change the natural history of the HCV infection, leading to a faster progression of the liver fibrosis.
OBJECTIVE: To evaluate and compare the fibrosis progression in two groups of patients (HCV/HIV coinfected and HCV monoinfected)
METHODS: Seventy patients HCV monoinfected and 26 patients HCV/HIV coinfected who had not undertaken HCV treatment and were submitted to serial percutaneous liver biopsies were retrospectively evaluated. There was no difference in the fibrosis progression between the two groups.
CONCLUSION: The fibrosis grade evolution was not worse in the coinfected patients. The immunosuppression absence and the shortest time period between the biopsies in the coinfected group are possible explanations.

Entities:  

Mesh:

Year:  2013        PMID: 23657302     DOI: 10.1590/s0004-28032013000100005

Source DB:  PubMed          Journal:  Arq Gastroenterol        ISSN: 0004-2803


  3 in total

Review 1.  Hepatitis C.

Authors:  Daniel P Webster; Paul Klenerman; Geoffrey M Dusheiko
Journal:  Lancet       Date:  2015-02-14       Impact factor: 79.321

Review 2.  Aging of the Liver: What This Means for Patients with HIV.

Authors:  Austin W Chan; Yuval A Patel; Steve Choi
Journal:  Curr HIV/AIDS Rep       Date:  2016-12       Impact factor: 5.071

3.  Impact of HIV-1 Infection on the Natural Progress of an Anti-HCV Positive Population in an Impoverished Village in China from 2009 to 2017.

Authors:  Xinjie Li; Yuantao Li; Yuqi Zhang; Yue Yin; Jing Tu; Qiang Xu; Hua Liang; Tao Shen
Journal:  Viruses       Date:  2022-07-26       Impact factor: 5.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.